; and (ii) uses the process, methodology, and timeline developed by the Committee under paragraph (2). (B) Timeframe The Committee shall issue a reasonable pricing determination under subparagraph (A) for a drug that, upon approval of an application under section 505(b) of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 355(b) ) or section 351(a) of the Public Health Service Act ( 42 U.S.C. 262(a) ), will be an applicable drug, taking into consideration the recommended timeframe under section 4(a)(2). (C) Reports to drug manufacturers For each reasonable pricing determination made under subparagraph (A), the Committee shall submit a report in writing to the applicable drug manufacturer outlining such determination. Each such report shall be made public, excluding any proprietary information. (4) Appointment of advisory committees The Committee may appoint permanent or ad hoc advisory committees as determined appropriate to assist in the work of the Committee. All members of any such advisory committee shall be subject to the same conflict of interest requirements as Committee members. (g) Annual reports The Committee shall submit an annual report to Congress and to the Secretary, and shall make the annual report available to the public. Each such report shall include— (1) a description of the activities conducted under this Act; (2) the budget of the Committee for the following year